iBio, Inc. (IBIO) Achieves Critical Technology Transfer Milestone
iBio develops and offers product applications of its iBioLaunch and iBioModulator platforms. It provides collaborators full support for turnkey implementation of its technology for both proprietary and biosimilar products. In addition, the company is developing select product candidates that have been derived from the iBioLaunch platform. The company today announced the achievement of a critical technology transfer milestone verified by an independent third party laboratory. The validation milestone showed proof that an independent party, without any guidance or assistance from iBio, could use the iBioLaunch system to reliably produce commercial yields of targeted biopharmaceuticals. iBio's business commitments to its licensees,…